NEWS RELEASE

HYFLUX ANNOUNCES POSITIVE RESULTS FROM ELO GEL CLINICAL STUDY

Singapore, 26 August 2016 – Hyflux Ltd ("Hyflux") is pleased to announce that its subsidiary, ELO Water Pte Ltd, has received the results of a clinical study conducted on the efficacy of ELO Gel on skin wrinkle, colour, elasticity, hydration and radiance on human skin.

This clinical study was conducted by Dermapro Skin Research Centre in Seoul, Korea, a clinical trial institute specialising in the evaluation of safety and efficacy testing of cosmetics, cosmeceuticals, and nutraceuticals on human skin.

Based on a study of twenty-two females aged between 49 and 54 years old, with ELO Gel applied morning and night on one side of the face over the trial period of 8 consecutive weeks of treatment, it was observed that skin wrinkle, colour, elasticity, hydration and radiance were significantly improved on the side of the face treated with ELO Gel. No adverse skin reaction was observed on any of the twenty-two subjects.

ELO Gel is an oxygen-rich lightweight gel formulated with ELO Water, which is produced using a proprietary process by ELO Water Pte Ltd.

The results of this study is not expected to have a material impact on Hyflux's financial performance in 2016.

- End -

About Hyflux

Hyflux is a global leader in sustainable solutions, focusing on the areas of water and energy. Headquartered and listed in Singapore, the Group has operations and projects in Southeast Asia, China, India, the Middle East, Africa and the Americas. Hyflux is committed to providing cost-effective and innovative solutions that contribute to resource optimisation and sustainable growth for communities and industries. A specialist in water treatment, Hyflux is distinctive in its ability to address the challenges at every point of the entire water value chain. The Group's track record includes Singapore's first water recycling plant and some of the world's largest seawater reverse osmosis desalination plants in Algeria, China and Singapore.

For more information, please visit www.hyflux.com

For media and analyst enquiries, please contact:

Bertha Cheung (Ms)
Corporate Communications
DID: (65) 3157 8031
Email:bertha_cheung@hyflux.com

Carol Huang (Ms)
Investor Relations
DID: (65) 3157 7635
Email: carol_huang@hyflux.com